Preview

Epilepsy and paroxysmal conditions

Advanced search

ZONEGRAN. NEW IN EVIDENTIAL PHARMACOTHERAPY OF EPILEPSY: OPPORTUNITIES AND EXPECTATIONS

Full Text:

Abstract

Abstract: this article represents review of literature devoted to a new antiepileptic drug Zonegran (zonisamide, ZNS). History of successful clinical use of ZNS in world practice lasts for 25 years. Zonisamide is on the Russian market from 2014 and is approved for monotherapy and adjunctive therapy of partial seizures with or without secondary generalization. This review is based on principles of evidence based medicine. Data of ZNS mechanism of action and pharmacokinetics are considered. Results of the most significant studies of ZNS efficacy and tolerability in drug-resistant focal epilepsy in adults and children in adjunctive and monotherapy regimes are presented. Possibilities of clinical use of ZNS in treatment of concomitant diseases are considered.

About the Author

I. G. Rudakova
Moscov regional scientific researth clinical institute names M.F. Vladimirskiy
Russian Federation


References

1. Instrukcija po primeneniju lekarstvennogo preparata dlja medicinskogo primenenija Zonegran ®. Registracionnyj nomer: LP-000739.

2. Pylaeva O.A., Muhin K.Ju. Primenenie novogo antijepilepticheskogo preparata – Zonegran ® (zonisamid) – v lechenii jepilepsii. Rus. zhurn. det. nevr. 2012; 7 (2): 13-34.

3. FMS RF. Chast 5 stat i 37 Federal nogo zakona ot 21.11. 2011 № 323-FZ «Ob osnovah ohrany zdorov ja grazhdan v Rossijskoj Federacii» (Sobranie zakonodatel stva Rossijskoj Federacii, 28.11.2011, № 48, st. 6724; 25.06.2012, № 26, st. 3442).

4. Baulac M., Brodie M.J., Patten A., Segieth J., Giorgi L. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol. 2012; 11: 579-588.

5. Baulac M. Introduction to zonisamide. Epilepsy Res. 2006; 68 (2): 3-9.

6. Baulac M., Leppik I.E. Efficacy and safety of adjunctive zonisamide therapy for refractory partial seizures. Epilepsy Res. 2007; 75 (2-3): 75-83.

7. Biton V. Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007; 30: 230-240.

8. Biton V. Zonisamide: newer antiepileptic agent with multiple of action. Expert Rev Neurother. 2004; 4 (6): 935-43.

9. Brodie M.J., Duncan R., Vespignani H., Solyom A., Bitenskyy V., Lucas C. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia. 2005; 46 (1): 31-41.

10. Chung, S., Wang N., Hank N. Comparative retention rates and long-term tolerability of new antiepileptic drugs. Seizure 2007; 16: 296-304.

11. Farooq M.U., Moore P.W., Bhatt A., Aburashed R., Kassab M.Y. Therapeutic role of zonisamide in neuropsychiatricdisorders. Mini Rev. Med. Chem. 2008; 8 (10): 968-75.

12. Faught E. Review of United States and European clinical trials of zonisamide in the treatment of refractory partial-onset seizures. Seizure. 2004; 13 (1): 59-65.

13. Glauser T., Ben-Menachem E., Bourgeois B., Cnaan A., Guerreiro C., Kalviainen R., Mattson R., French J.A., Perucca E., Tomson T. for the ILAE Subcommission on AED Guidelines. Epilepsia. 2013; 54 (3): 551-63.

14. GlaxoSmithKline UK. Trobalt summary of product characteristics. 28th March 2011.

15. Guerrini R., Rjsati A. Segieth J., Pellacani S., Bradshaw R., Giorgi L. A randomized phase III trial of adjunctive zonisamide in pediatric patients with partial epilepsy. Epilepsia. 2013; 54 (8): 1473-1480.

16. Helmstaedter C., Stefan H., Witt J.A. Quality of life in patients with partial-onset seizures under adjunctive therapy with zonisamide: results from a prospective non-interventional surveillance study. Epileptic Disord. 2011; 13: 263-76.

17. Holder J.L, Wilfong A.A. Zonisamide in thetreatment of epilepsy. Expert Opin Pharmacoter. 2011; 12 (16): 2573-81.

18. Janssen-Cilag Ltd. Topamax summary of product characteristics. 24thNovember 2010.

19. Janszky J. Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases. Ideggyogy Sz. 2009; 62 (11-12): 383-9.

20. Kim H.L., Aldridge J., Rho J.M. Clinical experience with zonisamide monotherapy and adjunctive therapy in children with epilepsy at a tertiary care referral center. J. Child Neurol. 2005; 20 (3): 212-9.

21. Kim L.G., Johnson T.L., Marson A.G., Chadwick D.W. Prediction of risk of seizure recurrence after a single seizure and early epilepsy: further results from the MESS trial. Lancet. Neurol. 2006; 5 (4): 317.

22. Lee Y.J., Kang H.C., Seo J.H., Lee J.S., Kim H.D. Efficacy and tolerability of adjunctive therapy with zonisamide in childhood intractable epilepsy. Brain Dev. 2010; 32 (3): 208-12.

23. Leppik I.E. Zonisamide: chemistry, mechanismofaction, andpharmacokinetics. Seizure. 2004; 13 (1): 5-9.

24. Novartis Pharmaceuticals UK Ltd. Tegretolchewtabs 100 mg, 200 mg, Tegretol tablets 100 mg, 200 mg, 400 mg summary of product characteristics. 17th November 2009.

25. Ohtahara S. Zonisamide in the management of epilepsy – Japanese experience. Epilepsy Res. 2006; 68 (2): 25-33.

26. Ohtahara S., Yamatogi Y. Safety of zonisamide therapy: prospective follow-up survey. Seizure. 2004; 13 (1): 50-5.

27. Sackellares J.C., Ramsay R.E., Wilder B.J., Browne T.R. 3rd., Shellenberger M.K. Randomized, controlled clinicaltrial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia. 2004; 45 (6): 610-7.

28. Schmidt D., Jacob R., Loiseau P., Deisenhammer E., Klinger D., Despland A., Egli M., Bauer G., Stenzel E., Blankenhorn V. . Zonizamide for add-on treatment of refractory partial epilepsy; a European double – blind trial. Epilepsy Res 1993; 15: 67-73.

29. Sills G., Brodie M. Pharmacokinetics and druginteractions with zonisamide. Epilepsia. 2007; 48 (3): 435-41.

30. Sobieszek G., Borowicz K.K., Kimber-Trojnar Z., Malek R., Piskorska B., Czuczwar S.J. Zonisamide: a newantiepileptic drug . Pol. J. Pharmacol. 2003; 55 (5): 683-9.

31. Trinca E., Giorgi L., Patten A., Segieth J. Safety and tolerability of zonisamide in elderly patients with epilepsy. 2013. Acta Neurol Scand DOI: 10.1111/ ane.12162.

32. UCB Pharma Ltd. Keppra 250, 500, 750 and 1,000 mg film-coated tablets, 100 mg/ml oral solution and 100 mg/ml concentrate for solution for infusion summary of product characteristics. UCB Pharma Ltd; 29th June 2011.

33. UCB Pharma Ltd. Vimpat 50 mg, 100 mg, 150 mg & 200 mg film-coated tablets, 15 mg/ml syrup and 10 mg/ml solution for infusion summary of product characteristics. May 2011.

34. Wroe S. Zonisamide and renal calculi in patients with epilepsy: how big an issue? Curr. Med. Res. Opin. 2007; 23 (8): 1765-73.

35. You S.J., Kang H.C., Kim H.D., Lee H.S., Ko T.S. Clinical efficacy of zonisamide in Lennox-Gastaut syndrome: Korean multicentric experience. Brain Dev. 2008; 30 (4): 287-90.

36. Yum M.S., Ko T.S. Zonisamide in West syndrome: an open label study. Epileptic Disord. 2009; 11 (4): 339-44.


For citation:


Rudakova I.G. ZONEGRAN. NEW IN EVIDENTIAL PHARMACOTHERAPY OF EPILEPSY: OPPORTUNITIES AND EXPECTATIONS. Epilepsy and paroxysmal conditions. 2014;6(1):64-69. (In Russ.)

Views: 182


ISSN 2077-8333 (Print)
ISSN 2311-4088 (Online)